Digene CancerTest Receives Health Plan Approval
The company's cervical cancer test was approved and instituted by three major health plans.
Digene
(DIGE)
said that its human papillomavirus (HPV) DNA test has been approved and instituted by three regional health plans.
The Digene Hybrid Capture DNA test is used as part of a cervical cancer screening, and the test has been instituted by the Excellus Health Plan in upstate New York, the HIP Health Plan in the New York City area, and John Deere Health Care in Illinois, Tennesses, and Virginia.
The agreements call for the plans to use the test for women who test positive for borderline Pap results, identified as high risks for cervical cancer.
Shares of Digene closed at $34.20 before the announcement.
